

STROBE statement?checklist of items that should be included in reports of observational studies  
 For the paper with title: " Antipsychotics and acute pancreatitis – a population based study"

	Item No	Recommendation
<b>Title and abstract</b>		
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract <b>DONE</b> (b) Provide in the abstract an informative and balanced summary of what was done and what was found <b>DONE</b>
<b>Introduction</b>		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <b>DONE</b>
Objectives	3	State specific objectives, including any prespecified hypotheses <b>DONE</b>
<b>Methods</b>		
Study design	4	Present key elements of study design early in the paper <b>DONE</b>
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <b>DONE</b> <b>see Sources of data</b>
Participants	6	(a) <i>Cohort study?</i> Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study?</i> Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross sectional study?</i> Give the eligibility criteria, and the sources and methods of selection of participants <b>DONE see Case &amp; control identification</b> (b) <i>Cohort study?</i> For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study?</i> For matched studies, give matching criteria and the number of controls per case <b>NA</b>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <b>DONE see Case &amp; control identification &amp; Exposure to Antipsychotics drugs</b>
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <b>DONE see Sources of data</b>
Bias	9	Describe any efforts to address potential sources of bias <b>DONE see Case &amp; control identification</b>
Study size	10	Explain how the study size was arrived at <b>See Studydesign and Sources of data</b>
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <b>NA</b>
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <b>DONE see statistical method</b> (b) Describe any methods used to examine subgroups and interactions <b>DONE see statistical method</b> (c) Explain how missing data were addressed <b>DONE see statistics under Method</b> (d) <i>Cohort study?</i> If applicable, explain how loss to follow-up was addressed <i>Case-control study?</i> If applicable, explain how matching of cases and controls was addressed <i>Cross sectional study?</i> If applicable, describe analytical methods taking account of sampling strategy <b>NA</b> (e) Describe any sensitivity analyses <b>NA</b>
<b>Results</b>		
Participants	13*	(a) Report numbers of individuals at each stage of study?eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <b>DONE 1<sup>st</sup> paragraph Results</b> (b) Give reasons for non-participation at each stage <b>NA</b> (c) Consider use of a flow diagram <b>NA</b>
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <b>DONE Results and table1</b> (b) Indicate number of participants with missing data for each variable of interest <b>DONE See methods</b> (c) <i>Cohort study?</i> Summarise follow-up time (eg average and total amount) <b>NA</b>

Outcome data	15*	<p><i>Cohort study</i>?Report numbers of outcome events or summary measures over time <b>NA</b></p> <p><i>Case-control study</i>?Report numbers in each exposure category, or summary measures of exposure <b>DONE See table1</b></p> <p><i>Cross sectional study</i>?Report numbers of outcome events or summary measures <b>NA</b></p>
Main results	16	<p>(a) Report the numbers of individuals at each stage of the study?eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <b>NA</b></p> <p>(b) Give reasons for non-participation at each stage <b>NA</b></p> <p>(c) Consider use of a flow diagram <b>NA</b></p>
Other analyses	17	Report other analyses done?eg analyses of subgroups and interactions, and sensitivity analyses <b>DONE See last paragraph of the results</b>
<b>Discussion</b>		
Key results	18	Summarise key results with reference to study objectives <b>DONE in the very beginning of the discussion</b>
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <b>DONE 2nd paragraph discussion</b>
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <b>DONE, the rest of the discussion</b>
Generalisability	21	Discuss the generalisability (external validity) of the study results <b>Done see 2<sup>nd</sup> paragraph discussion</b>
<b>Other information</b>		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <b>DONE See funding.</b>